RP — Replicel Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00
- CA$3.38m
- CA$3.39m
- CA$0.35m
2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | Interim Report | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.42 | 0.053 | 0.052 | 0.238 | 0.43 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.075 | 0.052 | 0.064 | 0.061 | 0.082 |
Prepaid Expenses | |||||
Total Current Assets | 3 | 0.233 | 0.186 | 0.393 | 0.636 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.008 | 0.006 | 0.004 | 0.003 | 0.002 |
Long Term Notes Receivable | |||||
Total Assets | 3.23 | 0.505 | 0.421 | 0.592 | 0.798 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.53 | 2.27 | 2.24 | 1.67 | 2.07 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.68 | 4.93 | 5.48 | 7.43 | 6.71 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -0.455 | -4.43 | -5.06 | -6.84 | -5.92 |
Total Liabilities & Shareholders' Equity | 3.23 | 0.505 | 0.421 | 0.592 | 0.798 |
Total Common Shares Outstanding |